Sunshine Biopharma appoints new COO and Chief Development Officer at annual meeting

Sunshine Biopharma Inc.

Marc Beaudoin appointed COO; Malek Chamoun appointed Chief Development Officer, effective Jan 25, 2024.
Dr. Abderrazzak Merzouki moved from COO to Chief Science Officer.
Camille Sebaaly continues as CFO/Secretary; Dr. Steve Slilaty continues as President/CEO.
Malek Chamoun is also President of subsidiary Nora Pharma Inc., acquired in Oct 2022.
Beaudoin has 10 years at Sandoz Canada; Chamoun is a CPA with HEC Montreal degree.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Role change

Dr. Abderrazzak Merzouki

Chief Science Officer

SBFM · Sunshine Biopharma Inc.

Effective: 2024-01-25
Filed: January 30, 2024, 6:59 PM ET

Previously, Dr. Merzouki had held the position of Chief Operating Officer.

Appointed

Malek Chamoun

Chief Development Officer

SBFM · Sunshine Biopharma Inc.

Effective: 2024-01-25
Filed: January 30, 2024, 6:59 PM ET

Malek Chamoun, age 39 , was appointed as our Chief Development Officer in January 2024.

Appointed

Marc Beaudoin

Chief Operating Officer

SBFM · Sunshine Biopharma Inc.

Effective: 2024-01-25
Filed: January 30, 2024, 6:59 PM ET

Marc Beaudoin, age 57, was appointed as our Chief Operating Officer in January 2024.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Dr. Abderrazzak Merzouki was elected as Chief Science Officer at Sunshine Biopharma Inc..

Action: elected
Role: Chief Science Officer

Exact text from the filing

Previously, Dr. Merzouki had held the position of Chief Operating Officer.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Malek Chamoun was appointed as Chief Development Officer at Sunshine Biopharma Inc..

Action: appointed
Role: Chief Development Officer

Exact text from the filing

Malek Chamoun, age 39 , was appointed as our Chief Development Officer in January 2024.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Marc Beaudoin was appointed as Chief Operating Officer at Sunshine Biopharma Inc..

Action: appointed
Role: Chief Operating Officer

Exact text from the filing

Marc Beaudoin, age 57, was appointed as our Chief Operating Officer in January 2024.

View on SEC.gov

Sunshine Biopharma Inc. filing history →

Source: SEC EDGAR

accession 0001683168-24-000540

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.